Biotechnology - Publications - Faculty & Research - Harvard Business School

Filter Results: (446)

Filter Results: (446)

Show Results For

← Page 3 of 446 Results →

Sort by

Are you looking for?

→Search All HBS Web

Teaching Interest

Overview

Since coming to HBS, my teaching interests have centered around the intersection of science and business: entrepreneurship, management, and strategy. More recently, i have become more engaged in considering the emergence of new university models for the translation... View Details

Keywords: Science Business; Biotechnology; Pharmaceuticals; Innovation

December 2014 (Revised February 2017)
Case

Simplot Plant Sciences: Designing a Better Potato

By: Jose B. Alvarez and Mary Shelman

Privately held Simplot has developed a new genetically engineered potato that substantially reduces waste and does not turn brown after cutting. Unlike other GMOs, it does not contain foreign genes. The case describes the company's commercialization plans in light of... View Details

Keywords: GMO; Sustainability; Agribusiness; Biotechnology; Food And Environment; Plant-Based Agribusiness; Food; Disruptive Innovation; Technological Innovation; Marketing; Product Positioning; Genetics; Value Creation; Agriculture and Agribusiness Industry; United States

November 2017
Case

BeiGene

By: Willy Shih and Jimmy Zhang

BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window... View Details

Keywords: Biotechnology; Pharmaceutical Company; Pharmaceuticals; China; Regulatory Environment; Business Strategy; Business Startups; Innovation Strategy; Situation or Environment; Pharmaceutical Industry; China

June 2020
Case

Breakthroughs at Blueprint Medicines

By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma

Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details

Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts

January 2018
Supplement

BeiGene Supplemental PowerPoint

By: Willy C. Shih and Jimmy Zhang

BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window... View Details

Keywords: Biotechnology; Pharmaceutical Company; Pharmaceuticals; China; Regulatory Environment; Business Strategy; Innovation Strategy; Situation or Environment; Biotechnology Industry; Biotechnology Industry; China

August 2013 (Revised October 2013)
Case

MedImmune Ventures

By: Richard G. Hamermesh and David Lane

Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer... View Details

Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; Corporate Venturing; Biotechnology; Venture Investing; Venture Capital; Health Care and Treatment; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; United States; Australia; Europe; London

March 2018 (Revised May 2018)
Case

Celgene

By: Malcolm Baker and Emily McComb

In February 2011, Adam Koppel, a managing director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm’s position in Celgene Corporation. News has emerged that raises potential safety concerns associated with... View Details

Keywords: Life Sciences; Biotechnology; Public Market Investing; Celgene; Revlimid; Hedge Fund; Growth Stocks; Valuation; Investment; Decision Choices and Conditions; Analysis; Biotechnology Industry

January 2021
Case

Takeda Pharmaceutical Company Limited (A)

By: David J. Collis, Nobuo Sato and Akiko Kanno

This case follows Christophe Weber, President and CEO of Takeda Pharmaceutical Company Limited, a leading pharmaceutical company headquartered in Tokyo, Japan, as Takeda considers acquiring Shire Plc, a biotech company based in Ireland. The acquisition would turn... View Details

Keywords: Pharmaceutical Companies; Pharmaceuticals; Biotech; Biotechnology; M＆A; Mergers ＆ Acquisitions; R＆D; Talent Management; Mergers and Acquisitions; Globalization; Management; Global Strategy; Talent and Talent Management; Biotechnology Industry; Biotechnology Industry; Japan; Asia

November 2016
Supplement

Alnylam Pharmaceuticals: Building Value from the IP Estate (B)

By: Vicki Sato, Willy Shih and Matt Higgins

The leader of a pioneering biotech company in the siRNA space weighs his options for scaling production capacity in advance of an anticipated commercial launch. Operational complexity and relative merits of in-house manufacturing versus a contractor model are... View Details

Keywords: Pharmaceutical Companies; Pharmaceutical Industry; Biotech; Biotechnology; Operational Complexity; Strategy; Manufacturing; Production; Strategic Planning; Intellectual Property; Biotechnology Industry; United States

March 2018 (Revised May 2018)
Supplement

Celgene (B)

By: Malcolm Baker and Emily McComb

Supplements the (A) case. View Details

Keywords: Life Sciences; Biotechnology; Public Market Investing; Celgene; Revlimid; Hedge Fund; Growth Stocks; Valuation; Investment; Decision Choices and Conditions; Analysis; Biotechnology Industry

October 2012
Teaching Plan

Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech (TP)

By: Robert F. Higgins

This is the teaching note related to HBS case 808005. In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates... View Details

Keywords: Venture Philanthropy; Biotechnology; Funding Philanthropy Venture; Cystic Fibrosis; Foundations; Pharmaceuticals; Mergers and Acquisitions; For-Profit Firms; Venture Capital; Philanthropy and Charitable Giving; Science-Based Business; Nonprofit Organizations; Biotechnology Industry; Biotechnology Industry; United States; San Diego

January 2014 (Revised June 2015)
Teaching Note

Amgen Inc: Pursuing Innovation and Imitation? (A), (B)

By: Ian Mackenzie

Keywords: Strategic Change; Biosimilars; Medical Biotechnology; Emerging Markets; Industry Structure; Uncertainty; Strategy Development; Implementation; Corporate Strategy; Biotechnology Industry; Biotechnology Industry; United States

April 2018
Supplement

Celgene

By: Malcolm Baker and Emily R. McComb

In February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm’s position in Celgene Corporation. News has emerged that raises potential safety concerns associated with... View Details

Keywords: Life Sciences; Biotechnology; Public Market Investing; Celgene; Revlimid; Hedge Fund; Growth Stocks; Valuation; Investment; Decision Choices and Conditions; Analysis

January 2014
Supplement

Fred Khosravi and AccessClosure (C)

By: Richard Hamermesh and Lauren Barley

On September 11, 2013, the three-judge panel of the U.S. Court of Appeals for the Federal Circuit denied St. Jude's request to rehear an appeal on the "double patenting" ruling for the '439 patent. Further, it removed the injunction threat that was hanging over the... View Details

Keywords: Medical Devices; Vascular Closure Device; Patent Litigation; Patenting; Biomedical Research; Biotechnology; Biotech; Technological Innovation; Patents; Health Care and Treatment; Biotechnology Industry; United States

October 2013 (Revised January 2014)
Supplement

Fred Khosravi and AccessClosure (B)

By: Richard G. Hamermesh and Lauren Barley

It was January 2013, and Fred Khosravi, chairman of the board of AccessClosure Inc., wondered what the new year had in store for him and AccessClosure, the company he founded in late 2002. Khosravi was cautiously optimistic—the Mountain View, California-based medical... View Details

Keywords: Medical Devices; Vascular Closure Device; Patent Litigation; Patenting; Biomedical Research; Biotechnology; Biotech; Technological Innovation; Patents; Health Care and Treatment; Biotechnology Industry; United States; California

January 2021
Supplement

Takeda Pharmaceutical Company Limited (B)

By: David J. Collis, Nobuo Sato and Akiko Kanno

This case is a follow up to HBS Case No. 721-373, Takeda Pharmaceutical Company Limited (A). Following the events of the previous case, Takeda reached an agreement to acquire Ireland-based Shire Plc. The case follows some of the achievements and challenges Takeda and... View Details

Keywords: Pharmaceutical Companies; Pharmaceuticals; M＆A; Mergers ＆ Acquisitions; Biotech; Biotechnology; R＆D; Talent Management; Mergers and Acquisitions; Globalization; Global Strategy; Talent and Talent Management; Strategy; Biotechnology Industry; Biotechnology Industry; Japan; Asia

February 2015 (Revised November 2015)
Case

Building an Integrated Biopharma Company: Crucell (A)

By: Richard G. Hamermesh, Marianne Van Der Steen and Susan S. Harmeling

By 2009, Crucell had become the largest biopharma company in the Netherlands and a symbol of national pride. The case traces the evolution of the company from a University spin-off into a fully-integrated company. Crucell's success, particularly in the vaccine space,... View Details

Keywords: Biotechnology; Biopharmacy Company; Licensing; Licensing Agreements In Biopharmacy; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Partners and Partnerships; Entrepreneurship; Growth and Development Strategy; Biotechnology Industry; Biotechnology Industry; Netherlands

February 2015 (Revised November 2015)
Supplement

Building an Integrated Biopharma Company: Crucell (B)

By: Richard G. Hamermesh, Marianne Van Der Steen and Susan Harmeling

The Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8... View Details

Keywords: Biotechnology; Biopharmacy Company; Licensing Agreements In Biopharmacy; Licensing; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Entrepreneurship; Health Care and Treatment; Acquisition; Innovation and Invention; Biotechnology Industry; Biotechnology Industry

November 2002 (Revised June 2003)
Case

Monsanto: Leadership in a New Environment

By: Ray A. Goldberg, James Weber and James M Beagle

Monsanto is the biotechnology leader in agriculture. How does it use its leadership in Round Up to fund long-term research and development in biotechnology that is acceptable to the priority system of consumers in different parts of the world? Includes color exhibits. View Details

Keywords: Research and Development; Science-Based Business; Food; Business or Company Management; Agribusiness; Industry Growth; Customer Focus and Relationships; Globalization; Leadership; Biotechnology Industry; Biotechnology Industry; United States

January 1994 (Revised November 1997)
Case

Aberlyn Capital Management: July 1993

By: Josh Lerner and Peter Tufano

Aberlyn Capital Management, a venture leasing firm specializing in providing capital to biotechnology firms, proposes to introduce a new product. Aberlyn will base a lease on an intangible product: the patent of a biotechnology firm. This poses a series of short and... View Details

Keywords: Financing and Loans; Valuation; Product Launch; Problems and Challenges; Patents; Financial Instruments; Biotechnology Industry; Biotechnology Industry

←
3
4
…
22
23
→